StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $2.42 | $2.69 | +11.16% | 0.1M |
| 05-14 | $2.69 | $2.58 | -4.09% | 0.3M |
| 05-15 | $2.57 | $2.50 | -2.72% | 0.0M |
| 05-18 | $2.51 | $2.51 | +0.00% | 0.0M |
| 05-19 | $2.50 | $2.52 | +0.80% | 0.0M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
No sell-side coverage available for KPRX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Fundamentals not available for KPRX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Each factor shows KPRX's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2026 (Est.) Expected 2026-08-06 | Annual 2021 2021-12-31 | Annual 2020 2020-12-31 | Q3 2020 2020-09-30 | Q2 2020 2020-06-30 |
|---|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $12.06K | $0.00 | $0.00 |
Operating Income | Not available | $-14.24M | $-6.87M | $-5.70M | $-3.69M |
Net Income | Not available | $-13.77M | $-6.86M | $-5.68M | $-3.67M |
EPS (Diluted) | $-0.63 | $-57.12 | $-1.49 | $-1.25 | Not available |
Total Assets | Not available | $20.13M | $15.30M | $9.25M | $10.97M |
Total Liabilities | Not available | $5.55M | $5.57M | $3.28M | $3.17M |
Cash & Equivalents | Not available | $7.85M | $1.19M | $2.93M | $4.69M |
Free Cash Flow OCF − CapEx | Not available | $-10.74M | $-7.34M | Not available | Not available |
Shares Outstanding | Not available | 316.60K | 5.56M | 4.63M | 4.63M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.